The use of a new monoclonal enzyme immuiioassay (EIA) for the carcinoembryonic antigen' (CEA) (Enzymun^Test® CEA) was eväluated in a multi-centre study. Fifteen different laboratories participated in the study. Data fröm the investigation were analysed in terms of precision, sensitivity, specificity and correlation with other test methods. The intra-assay coefficient of Variation was between 1.3% at 23.0 g/l CEA and 13.9% at l^g/l CEA. Iiiter-assay reproducibility ranged from 3.6% to 19.2%. The apparent sensitivity of the new EIA for CEA was approx. 0.5 g/l CEA. The findings indicate that lipaemic and haemolytic sera and samples taken from icteric, rheumatic and dialysis patients did not have any influence on the results. There was no evidence that drugs commonly used in the treatment of carcinoma patients have any influence on the assay results. A good correlation between the new EIA for CEA and six other CEA enzyme "immunoassay or radioiinmunoassay methods was registered. These results seem to be of significance in particiflar for the monitoring of therapy for carcinoma patients. The new EIA for CEA exhibits a high degree of sensitivity, specificity and reproducibility.
Introduction
Carcinoembryonic antigen (CEA) is a glycoprotein consisting of a polypeptide chain with a molecular weight of 180 kD. It has a carbohydrate content of 40 to 60%. The protein moiety of CEA is a single polypeptide chain with multiple intrachain disulphide bonds. The pure peptide chain consists of some 800 amino acids (1) . The physiological function of CEA is not known.
CEA is normally detectable only in very low concentrations in the serum of healthy men and women. Pathologically raised CEA serum levels are encountered in conjunction with CEA-producing tumours. CEA has been used for monitoring patients with colorectal carcinoma, and its role äs a tumour marker and äs diagnostic tool in this disease is well documented (2) . Recent reports suggest that CEA may also be used äs a tumour marker for cancers other than colorectal (3) . It was also noted to be of use in gynaecological tumours (4) (5) (6) .
Since the first report of a radioimmunoassay System (7), other radioimmunological methods, in addition to enzyme immunoassay Systems, have been described. Some studies show a strong correlation between different assay Systems (8, 9, 10) , others (11, 12) reveal a low-degree of correlation or even lack of comparability.
The aim of this multi-centre study was to investigate the sensitivity, the specificity and reproducibility of a new CEA enzyme immunoassay (EIA) using monoclonal antibodies (Enzymun-Test® CEA). In addition, the investigation was aimed at comparing CEA serum levels estimated by this new EIA with other enzyme immunoassay and radioimmunoassay methods.
This multi-centre form of organization was used to ascertain whether data obtained with this new EIA is comparable with results obtained by other assay Systems. We were prompted to investigate this question, since patients in whom serial CEA determinations are indicated are not necessarily investigated by the same laboratory. Another aim of the multi-centre study was to define reference ranges, to describe CEA serum levels in various malignancies and to evaluate whether this new CEA EIA method can be used for monitoring carcinoma patients.
Materials and Methods

Immunoassay teehnology
The assay is based on the Sandwich EIA principle using solid phase and enzyme-labelled monoclonal antibodies (13).
Reagents
Test kit "Enzymun-Test® CEA", cat. no. 204501, from Boehringer Mannheim, D-6800 Mannheim, containing incubation buffer 100 mmol/1 acetate buffef, pH 5.7, anti-CEA-peroxidase-conjugate > 100 U/l; Substrate buffer 100 mmöl/1 phosphate-citrate-buffer, pH 4.4; 3.2 mmol/1 sodium perborate, 1.9 mmol/1 di-ammonium 2.2'-azino-bis (3-ethylbenzothiazoline-6-sulphonate) (ABTS®); 5 Standards CEA hl horse serum, cpncentration 0-55 g/l; cpntrol serum, CEA in horse serum; 100 plastic vials coated with CEA antibody, binding capacity > 200 ng CEA per vial. The working solution is prepared according to the manufacturer's instructions.
Assay protocol 1. Samples or Standards (100 ) were incübated with l ml antl·· CEA-conjugate solution in the plastic tübes for 2 hours at 20-25°C.
2. Vial contents were aspirated and plastic tubes were rinsed three times with tap water.
3. ABTS® Substrate solution (l ml) was added and incubatipn continued for another 60 inimites at 20-25 °C.
4. Absorbance was read at 405 mn and CEA concentrations were calculated from the calibration curve.
Standard calibration
The working Standards of the test kit were prepared in horse serum. They were calibrated agäinst the first international reference preparation of CEA (14) (16) . The purity of the CEA preparation was greater than 90% äs judged by analytical pölyacryl-amide gel electrophoresis.
Monoclonal antibody production
Immunization
The procedure ofAccolla et al. (17) was used. Balb/c mice were immunized twice with 15 ng purified CEA in complete Freunds adjuvant per injection in intervals of 14 weeks. One day after the second injection the mice were immunized with 100 g CEA in saline intraperitoneally. The following day the mice received a final booster dose of 150 g CEA in saline mtraperitoneally. Three days later the spieen cells were fused. (18) . The reactivity with non-specific crossreacting antigen (NCA) (19) is less than 0.05% for Tu 2 and less than 0.005% for Tu 3. Granulocytes do not react with either antibody.
Evaluation procedure Enzymun-Test® CEA was assayed in 15 laboratories. All serum samples were determined in duplicate.
Four laboratories followed the manual test procedure, 11 laboratories were equipped with Enzymun-Test® System ES 22 (20) , a modular batch analyser System (ES 22, Boehringer Mannheim GmbH). Besides one self-developed CEA radioimmunoassay the following kits were used:
RIA-gnost® CEA, Behringwerke AG; CEA EIA Test, R che; Abbott CEA-EIA polyclonal and Abbott CEA monoclonal, Abbott laboratories; Phadebas CEA PRIST® radioimmunoassay, Pharmacia GmbH. 
Results
Precision
The intra-assay precision determined in human sera with concentrations of up to 30.3 μ §/1 CEA is shown in figure 1 . The coefficients of Variation ranged ffom 1.3% at 23.0 μg/l CEA to 13.9% at 1.3 μκ/l CEA. To determine the lowest concentration of CEA statistically distinguishable from CEA-free specimens, the zero Standard of the kit was assayed in single measurements (n = 20). The detection limit of CEA is defined s the three-fold Standard deviation of absorbance of zero Standard calculated from the Standard curve. A sensitivity of less than 0.5 μg/l CEA was noted ( fig. 3 ).
Specificity
Icteric, lipaemic, haemolytic sera and specimens from patients suffering from rheumatic diseases and dialysed patients were diluted with normal human serum and then spiked with CEA. The recovery of CEA ranged from 94 to 104%. These results were similar to those obtained in the recovery study (tab.
2). No interference by bilirübin (428 / ), lipids (triacylglycerol concentration 10.26 mmol/1) haemoglobin (l g/l), rheumatic factors or by dialysis cöuld be observed.
The influence of drugs was assayed for the 37 effektive components most frequently used (21) äs well äs Diethylstilbestrol, Cisplatin, Doxorubicin, Etopösid, Fluorouracil, Aminoglutethimid, Tamoxifen and Ifosfamid. Normal serum was spiked with CEA and with these substances. None of the dfugs affected the reproducibility or accuracy of the assay. Table 3 shows a comparison of the results obtained by En2ymun-Test® CEA and by 5 other CEA ässäys. Regression parameters are calculated using a biometric regression procedüre in accordance with Passing & Bablok (22) . A good correlation was observed for the enzyme immunoassäys and the self-developed radioî mmunoassay, except for the results of laboratory 8 (low CEA valües). Laboratories 7 and 9 did not collect enough data for statistical evaluation; laboratories 6,11 and 12 did not take part in the correlation trial. Two examples of gräphical correlations are demonstrated in figures 4 and 5.
Correlation studies
Distribution of CEA valües CEA valües were determined in a group of 541 healthy control subjects (tab. 4) äs well äs in 590 patients with confirmed carcinoma and in 146 patients with non-malignant diseases (tab. 5). No Tab. 3. Correlation between Enzymun-Test® CEA (x) and 6 different EIA and RIA kits (y) using a biometric regression procedufe. 
Recovery
The recovery was assayed in spiked human sera. Equal amounts of a solution of purified CEA (58 g/l) and human sera containing 0-5.47 g/l CEA were mixed. The recovery valües obtained ranged from 88 to 106% (tab. 2).
Tab. 2. Recovery study using serum samples diluted l + l (by vol.) with a solution of purified CEA (58 g/l). Only part of the total number was differentiated in men, women, on-smokers and smokers. hitney) than the median of 1.5 g/l CEA for nonsmokers. Higher CEA values were found in men than in women. CEA levels were elevated in colorectal, mammary, pulmonary, medullary and thyroid carcinoma. Slightly elevated values were observed in patients with ovarian and cervical carcinoma. CEA was not elevated in patients with thyroid or bladder cancers. In the group of non-malignant patients CEA values ranges from 4.3-8.9 g/l (95% of all values).
Follow-up studies
In retrospective follow-up studies, time courses showing both increasing and decreasing CEA concentrations in patients with colon carcinoma were determined with Eijzymun-Test® CEA and the roütine assay (figs. 6, 7). A good correlation was found.
Discussion
The data of the present study indicate that CEA serum levels determined with the new EIA exhibit a high degree of correlation with other enzyme immunoassay or radioimmunoassay Systems. Some previous studies showed a good correlation between different assay methods (8, 9, 10) , whereas other investigations (11, 12) showed a low degree of correlation or even lack of compärability. The poor correlation repprted previously is partly due to the partial structural similärity of CEA with non-specific crossreaction antigen (NCA) and biliary glycoprotein (BGP). The good correlation öf the present assay System with other methods suggestsrthat patients do not have to be monitored by the same laboratofy. This result is of interest for the treätment of patients. In addition, a good specificity of the present CEA EIA System was noted. It was found that the assay was not influenced by icteric, haemolytie and lipaemic serum conditions. Furthermöre, drugs used for the therapy of cancer patients did not affect the reproducibility or accuracy of the assay. The multi-ceiitre structure of this investigation also revealed the great specificity of the present assay System, äs $hown by CEA data obtained from normal subjects and from patients with non-malignant diseases. A total of 95% of all CEA levels recorded in serum of 541 normal subjects were found to be between zero and 4.9 g/l A median of all values was determined at 1.5 /l CEA. In smokers the median was 2.3 §/1, significantly higher than in non-smokers (1.5 g/l CEA). But a cross-over of CEA concentrations is found between acute benign diseases and eafly tumour stages, äs already well documented for other CEA assay methods. The differentiation between benign diseases and late tumour stages is clinically not important. It was interesting to note that CEA levels were higher in males than in females. No explanation can be given for this at present. Present data combine to suggest that this new CEA EIA system, utilizing monoclonal antibodies, is a valuable diagnostic tool. This multi-centre study has shown that this assay System exhibits a high degree of sensitivity, specificity and reproducibility. The high degree of correlation with other assay Systems permits the comparison of data obtained by various other methods with this new CEA EIA.
